Standout Papers

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): l... 2022 2026 2023 2024169
  1. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial (2022)
    Robert J. Motzer, Thomas Powles et al. The Lancet Oncology

Immediate Impact

40 standout
Sub-graph 1 of 20

Citing Papers

Multi-OMICS approaches in cancer biology: New era in cancer therapy
2024 Standout
Tumor biomarkers for diagnosis, prognosis and targeted therapy
2024 Standout
2 intermediate papers

Works of Christopher Hocking being referenced

Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer
2013

Author Peers

Author Last Decade Papers Cites
Christopher Hocking 170 178 84 103 15 320
A. Iop 274 149 60 50 21 362
Qianru Li 118 89 58 113 23 306
Capucine Baldini 178 87 45 34 19 319
Keith M. Wirth 147 86 167 57 20 320
Yi Wang 111 211 67 102 19 371
Gary Zeger 154 148 53 59 19 308
Tomohiro Funakoshi 109 109 49 94 11 320
Riaz Alvi 254 93 65 83 15 360
Mengxue Hu 72 109 61 77 17 329
Emma Chen Sasse 125 122 39 57 19 282

All Works

Loading papers...

Rankless by CCL
2026